177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

被引：7
|
作者：
Rahbar, Kambiz [1 ]
Ahmadzadehfar, Hojjat [2 ]
Boegemann, Martin [3 ]
机构：
[1] Univ Hosp Muenster, Dept Nucl Med, D-48149 Munster, Germany
[2] Univ Hosp Bonn, Dept Nucl Med, Bonn, Germany
[3] Univ Hosp Muenster, Dept Urol, Munster, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2018年 / 45卷 / 03期
关键词：
D O I：
10.1007/s00259-017-3892-0
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：513 / 514
页数：2
相关论文
共 50 条
  • [1] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Kambiz Rahbar
    Hojjat Ahmadzadehfar
    Martin Boegemann
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 513 - 514
  • [2] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Rahbar, Kambiz
    Boegemann, Martin
    Ahmadzadehfar, Hojjat
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 166 - 167
  • [3] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Kambiz Rahbar
    Martin Bögemann
    Hojjat Ahmadzadehfar
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 166 - 167
  • [4] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response Reply
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Tripathi, Madhavi
    Bal, Chandrasekhal
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 168 - 169
  • [5] Safety and efficacy of 177lu-PSMA-617 radioligand therapy in patients with mCRPC: A multicenter study.
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Kratochwil, Clemens
    Baum, Richard P.
    Schmidt, Matthias
    Pfestroff, Andreas
    Prasad, Vikas
    Heinzel, Aelxander
    Ruf, Juri
    Eveslage, Maria
    Boegemann, Martin
    Fendler, Wolfgang
    Krause, Bernd J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [6] 177Lu-PSMA-617 vs Cabazitaxel in MCRPC
    不详
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (04) : 13N - 13N
  • [7] A randomized phase 2 trial in progress of flexible and extended dosing of 177Lu-PSMA-617 molecular radioligand therapy in mCRPC (FLEX-MRT)
    Holzgreve, Adrien
    Delker, Astrid
    Ells, Zachary
    Brosch-Lenz, Julia
    Zhu, Shaojun
    Lira, Stephanie
    Nikitas, John
    Grogan, Tristan
    Elashoff, David
    Unterrainer, Lena M.
    Dahlbom, Magnus
    Allen-Auerbach, Martin S.
    Czernin, Johannes
    Calais, Jeremie
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma
    Jueptner, Michael
    Marx, Marlies
    Zuhayra, Maaz
    Luetzen, Ulf
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2019, 58 (04): : 328 - 330
  • [9] Renal Function after Radioligand Treatment with 177Lu-PSMA-617
    Ngoc, Christina Nguyen
    Happel, Christian
    Davis, Karen
    Groener, Daniel
    Mader, Nicolai
    Mandel, Philipp
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [10] Radiation Dosimetry in 177Lu-PSMA-617 Therapy
    Jackson, Price
    Hofman, Michael
    McIntosh, Lachlan
    Buteau, James Patrick
    Kumar, Aravind Ravi
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2022, 52 (02) : 243 - 254
12345